Cardiovascular Research Market

Bradykinin

Bradykinin is an endogenous nonapeptide of the kallikrein-kinin system that acts at the B2 receptor to cause vasodilation, vascular permeability and pain, used in research as a provocation agent with no approved drug product.

BradykininB2 ReceptorKallikrein-Kinin SystemVasodilationResearch Reagent

Also referenced as: Bradykinin acetate, BRS-640

Also appears in: Immune

Public product evidence No certificate records are bound to a tracked Bradykinin product page A record counts here only when a vendor publishes a certificate against one of its own tracked Bradykinin product pages. Other certificates naming this compound may still exist — search the wider certificate database.
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Cardiovascular research

Primary research area: Cardiovascular. Also surfaces under Immune for browsing and discovery.

Body systems
Heart · Immune

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
2

Bradykinin acetate, BRS-640

Signal depth
Low

No FDA label signal · 100 trials · 1000 PubMed results

Promising

Bradykinin has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Bradykinin has 9 name-matched clinical trials (1 international) (highest phase: Phase 4) and 1000 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results. Note: 3 retracted publications in the literature.

🌍 1 international trial ⚠ 3 retracted publications
Human data
Phase 3
Trial quality
Randomized
Outcomes
Clinical outcomes
Replication
Multiple trials
Literature
Top-tier journals

Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →


What is Bradykinin?

Bradykinin is an endogenous nonapeptide with the sequence Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg and a molecular weight of about 1,060 Da. It is not a manufactured medicine but a signaling peptide generated inside the body. Plasma and tissue kallikreins release it, together with the related decapeptide lysyl-bradykinin, from precursor kininogens in response to tissue injury, and the two are the first set of bioactive kinins formed by the kallikrein-kinin system (Leeb-Lundberg et al., Pharmacological Reviews, 2005). The peptide was first isolated and named in 1949, when snake venom and trypsin were shown to liberate a hypotensive, smooth-muscle-stimulating factor from a plasma globulin, and the slow contraction it produced in gut smooth muscle gave it its name (Rocha e Silva et al., American Journal of Physiology, 1949).

Because bradykinin is a natural human peptide rather than a therapeutic agent, it has no approved drug product. Its practical roles are as an analytical reference peptide and as a controlled provocation agent in physiology studies, where it is infused into an artery, inhaled, or injected into skin to probe endothelial function, airway reactivity and pain pathways. The medicines built on this biology act against the pathway rather than supplying the peptide, among them the B2-receptor antagonist icatibant and the plasma-kallikrein inhibitor ecallantide, both used against the bradykinin-driven swelling of hereditary angioedema. For laboratory work the molecule is handled as the acetate salt.

How it works

  • B2 receptor agonism on endothelium drives vasodilation. Bradykinin acts at the B2 receptor, a ubiquitous, constitutively expressed G-protein-coupled receptor that signals through Gq to phospholipase C beta with calcium mobilization, and through Gi to inhibit adenylate cyclase and stimulate mitogen-activated protein kinase pathways (Leeb-Lundberg et al., Pharmacological Reviews, 2005). Cryo-EM structures of the human B2 receptor-Gq complex bound to bradykinin and to lysyl-bradykinin show both peptides adopting an S shape in a pocket whose aspartates and glutamates trap their basic ends, with the tail phenylalanine moving the conserved toggle switch that activates the receptor (Shen et al., Nature Communications, 2022).
  • Rapid inactivation by angiotensin-converting enzyme. Bradykinin is short-lived in plasma, hydrolyzed mainly by angiotensin-converting enzyme, historically named kininase II, and also by neprilysin (Skidgel and Erdos, Peptides, 2004). Blocking that degradation is why inhibitors of angiotensin-converting enzyme raise kinin levels, an effect tied to their characteristic cough and to drug-induced angioedema.
  • Permeability, pain and airway actions. Beyond vasodilation, kinins are proinflammatory peptides that mediate vascular leakage and pain responses to tissue injury, and kinin receptors have been implicated in edema, allergic asthma and rhinitis (Leeb-Lundberg et al., Pharmacological Reviews, 2005). Inhaled bradykinin constricts the airways in asthma, and that responsiveness rises after allergen exposure (Berman et al., Journal of Applied Physiology, 1995).
  • A second receptor acts on bradykinin metabolites. Carboxypeptidases convert bradykinin and lysyl-bradykinin into des-Arg9-bradykinin and Lys-des-Arg9-bradykinin, a second set of bioactive kinins that act at the B1 receptor, which sits at very low levels in healthy tissue and is induced after injury by proinflammatory cytokines such as interleukin-1 beta (Leeb-Lundberg et al., Pharmacological Reviews, 2005). Cryo-EM structures of the B1 and B2 receptors bound to antagonists identify three non-conserved residues at the base of the ligand pocket that confer subtype selectivity (Xia et al., Nature Communications, 2026).

Research status

Discovery and physiology. Bradykinin entered the literature in 1949 as a factor released from plasma globulin by snake venom and by trypsin, able to lower blood pressure and to stimulate smooth muscle (Rocha e Silva et al., American Journal of Physiology, 1949). The decades that followed mapped the kallikrein-kinin system and separated its two receptors, placing bradykinin and lysyl-bradykinin at the B2 receptor and their carboxypeptidase products at the inducible B1 receptor (Leeb-Lundberg et al., Pharmacological Reviews, 2005). Structural work has since resolved how agonists and antagonists engage both receptors (Shen et al., Nature Communications, 2022; Xia et al., Nature Communications, 2026).

Human vascular function. Bradykinin is a standard pharmacological probe of the endothelium. In a forearm study of 103 healthy subjects and 71 nonhypertensive subjects carrying multiple risk factors, intra-arterial infusion of a nitric oxide synthase inhibitor and of tetraethylammonium, which blocks calcium-activated potassium channels, each attenuated bradykinin-mediated vasodilation, and the potassium-channel contribution was the larger one in subjects with risk factors, indicating that hyperpolarizing mechanisms compensate when nitric oxide availability falls (Ozkor et al., Circulation, 2011). That program was registered as NCT00166166, listed bradykinin among its intra-arterial probes alongside acetylcholine and sodium nitroprusside, enrolled 174 participants, reached primary completion in January 2013, and was later terminated for limited clinical staff. A companion forearm study found that the hyperpolarizing component also mediates bradykinin-stimulated release of tissue plasminogen activator (Rahman et al., Journal of Vascular Research, 2014). Crosstalk with the renin-angiotensin system has been tested directly, with conflicting results: angiotensin-1-7 potentiated bradykinin-induced vasodilation in one forearm study (Ueda et al., Journal of Hypertension, 2001), while another found no effect of angiotensin-(1-7) on either vasodilator or tissue plasminogen activator responses to bradykinin (Wilsdorf et al., Hypertension, 2001). Because the vasodilator response is blunted when the endothelium is damaged, these forearm models remain a reference method for detecting endothelial dysfunction.

Airway reactivity. Inhaled bradykinin is used as a bronchoprovocation stimulus. In subjects with asthma studied before and after allergen challenge, airway responsiveness to inhaled bradykinin increased more than responsiveness to methacholine, a direct smooth-muscle agonist, which marks kinin sensitivity as a feature of allergen-driven airway inflammation rather than of airway caliber alone (Berman et al., Journal of Applied Physiology, 1995). That separation is why inhaled bradykinin has been retained as a research challenge agent distinct from the agents used in routine bronchial testing.

Inflammation and COVID-19. Interest in the kinin system widened during the COVID-19 pandemic. An analysis of gene expression in cells recovered from bronchoalveolar lavage fluid reported an atypical renin-angiotensin pattern, with reduced expression of angiotensin-converting enzyme alongside increases in ACE2, renin, kininogen, several activating kallikreins and both kinin receptors, a combination predicted to raise bradykinin levels in multiple tissues and to produce vasodilation, vascular permeability and hypotension; the authors described this as a bradykinin storm and proposed existing drugs as intervention points (Garvin et al., eLife, 2020). The model rests on transcriptomic inference rather than on measured kinin concentrations, and it stands as a mechanistic hypothesis.

Translation is through antagonism. No registered program administers bradykinin itself as a candidate medicine. The clinical translation of this biology blocks the peptide’s formation or its receptor instead. In hereditary angioedema, where unrestrained bradykinin generation causes the swelling, the B2-receptor antagonist icatibant and the plasma-kallikrein inhibitor ecallantide treat acute attacks, and raised kinin levels under inhibition of angiotensin-converting enzyme account for the angioedema seen with that drug class (Skidgel and Erdos, Peptides, 2004). Kinin-receptor antagonists have been pursued for angioedema, pancreatitis and asthma, and structural work on both receptor subtypes continues to guide the design of selective compounds (Xia et al., Nature Communications, 2026).

Regulatory position. As of November 2026, Drugs@FDA lists no application for bradykinin and DailyMed lists no US labeling for it. Active registered studies in this pathway test antagonists, kallikrein inhibitors and diagnostic assays rather than the peptide as a treatment, and bradykinin appears in registered protocols only as a physiological probe. It is handled as an endogenous mediator, an analytical reference peptide and a provocation agent used under research protocols.

Common dosage forms

  • Laboratory reference peptide. Bradykinin is supplied as the acetate salt in lyophilized solid form for analytical and laboratory research use.
  • Provocation preparations. Sterile solutions prepared for controlled physiology studies and given by investigators as intradermal injections, inhaled challenges or intra-arterial infusions.
  • No approved presentation. No marketed bradykinin drug product exists in any vial, ampoule, pen or oral presentation.

Key considerations

  • Regulatory status. The Research Market status reflects the absence of any Drugs@FDA application for bradykinin and the absence of a registered program developing the peptide as a US medicine. Approvals in this pathway cover receptor antagonists and kallikrein inhibitors rather than bradykinin itself, in the US and abroad.
  • The medicines are the antagonists, not the peptide. Practical value in the kinin system comes from blocking bradykinin’s formation or its B2 receptor, as with icatibant and ecallantide in hereditary angioedema, so supplying the peptide carries no therapeutic indication.
  • A research probe with real hazards. The actions that make bradykinin useful experimentally, among them hypotension, vascular leakage, pain and bronchoconstriction, are also why it is given only under controlled provocation protocols and why its receptor is pursued as a drug target instead.
  • Tied to the ACE and angiotensin axis. Angiotensin-converting enzyme degrades bradykinin, so kinin levels rise when that enzyme is inhibited, the mechanistic basis for the cough and angioedema associated with that drug class; the same axis includes angiotensin-ii and the counter-regulatory angiotensin-1-7, whose interaction with bradykinin responses in humans remains unsettled.
  • Naming. Bradykinin and bradykinin acetate denote the same nonapeptide, while lysyl-bradykinin and the des-Arg kinins that act at the B1 receptor are distinct molecules, and the antagonists and kallikrein inhibitors used clinically are separate compounds rather than forms of bradykinin.